Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lynette Sholl

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Histopathology|October 22, 2024
Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR)Wendy A Cooper, Fleur Webster, Kelly J Butnor, et al.
NPJ Precision Oncology|November 20, 2025
MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancerMing-Sound Tsao, Lynette Sholl, Michelle Shiller, et al.
JHLT Open|March 27, 2025
Radiological distribution patterns in restrictive chronic lung allograft dysfunction: Impact on survival across all phenotypesTaiki Fukuda, Yusei Nakamura, Shu-Chi Tseng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 25, 2022
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung AdenocarcinomaNatalie I Vokes, Emily Chambers, Tom Nguyen, et al.
American Journal of Respiratory and Critical Care Medicine|July 27, 2019
B Cell-Adaptive Immune Profile in Emphysema-Predominant Chronic Obstructive Pulmonary DiseaseJohn-Lawrence Sullivan, Bhavani Bagevalu, Carolyn Glass, et al.
JCO Precision Oncology|June 11, 2025
Efficacy and Safety of Tarlatamab in a Patient With Advanced Delta-Like Ligand 3-Positive Large Cell Neuroendocrine Lung Carcinoma and Untreated Brain Metastases: A Case ReportEleonora Gariazzo, Sanna Laaksonen, Stephanie Canty, et al.
The Journal of Thoracic and Cardiovascular Surgery|May 6, 2025
Lung cancer recurrence after neoadjuvant immunotherapyHao Li, Fatemehsadat Pezeshkian, Yue Xie, et al.
Journal of the American Medical Informatics Association : JAMIA|January 10, 2018
Interactive or static reports to guide clinical interpretation of cancer genomicsStacy W Gray, Jeffrey Gagan, Ethan Cerami, et al.
JCO Precision Oncology|October 7, 2024
Response to Crizotinib After Entrectinib Resistance in <i>ROS1</i>-Rearranged, <i>MET</i>-Amplified Lung AdenocarcinomaVictor R Vaz, Malini M Gandhi, Biagio Ricciuti, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancerXinan Wang, Biagio Ricciuti, Arielle Elkrief, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Histopathology|October 22, 2024
Data set for the reporting of lung cancer: recommendations from the International Collaboration on Cancer Reporting (ICCR)Wendy A Cooper, Fleur Webster, Kelly J Butnor, et al.
NPJ Precision Oncology|November 20, 2025
MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancerMing-Sound Tsao, Lynette Sholl, Michelle Shiller, et al.
JHLT Open|March 27, 2025
Radiological distribution patterns in restrictive chronic lung allograft dysfunction: Impact on survival across all phenotypesTaiki Fukuda, Yusei Nakamura, Shu-Chi Tseng, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 25, 2022
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung AdenocarcinomaNatalie I Vokes, Emily Chambers, Tom Nguyen, et al.
American Journal of Respiratory and Critical Care Medicine|July 27, 2019
B Cell-Adaptive Immune Profile in Emphysema-Predominant Chronic Obstructive Pulmonary DiseaseJohn-Lawrence Sullivan, Bhavani Bagevalu, Carolyn Glass, et al.
JCO Precision Oncology|June 11, 2025
Efficacy and Safety of Tarlatamab in a Patient With Advanced Delta-Like Ligand 3-Positive Large Cell Neuroendocrine Lung Carcinoma and Untreated Brain Metastases: A Case ReportEleonora Gariazzo, Sanna Laaksonen, Stephanie Canty, et al.
The Journal of Thoracic and Cardiovascular Surgery|May 6, 2025
Lung cancer recurrence after neoadjuvant immunotherapyHao Li, Fatemehsadat Pezeshkian, Yue Xie, et al.
Journal of the American Medical Informatics Association : JAMIA|January 10, 2018
Interactive or static reports to guide clinical interpretation of cancer genomicsStacy W Gray, Jeffrey Gagan, Ethan Cerami, et al.
JCO Precision Oncology|October 7, 2024
Response to Crizotinib After Entrectinib Resistance in <i>ROS1</i>-Rearranged, <i>MET</i>-Amplified Lung AdenocarcinomaVictor R Vaz, Malini M Gandhi, Biagio Ricciuti, et al.
Journal for Immunotherapy of Cancer|December 21, 2025
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung cancerXinan Wang, Biagio Ricciuti, Arielle Elkrief, et al.
Pageof 7